智翔金泰：泰利奇拜单抗注射液新药上市申请获受理

Core Viewpoint - Zhixiang Jintai (688443) announced that its drug Talichibai Injection (GR1802) has met the primary endpoint in a Phase III clinical trial for moderate to severe atopic dermatitis in adults, and the new drug application has been accepted by the National Medical Products Administration (NMPA) [1] Group 1 - The Phase III clinical trial for Talichibai Injection (GR1802) achieved its primary endpoint [1] - The company has submitted a new drug application for the indication to the NMPA, which has been accepted [1] - As of the announcement date, only two other drugs targeting the same indication have been approved for marketing in China [1]